摘要
文章旨在探讨血清micro RNA-103、Dicer1在上皮性卵巢癌中的表达及意义。收集2013年4月至2015年12月于该院接受治疗58例上皮性卵巢癌患者设为研究组,并同期收集36例健康体检者设为对照组,采用实时荧光定量逆转录聚合酶链反应(Real-time RT-PCR)检测血清micro RNA-103(mi R-103)和Dicer1水平。分析两种生物标志物在上皮性卵巢癌中的表达,及其与临床病理特征的相关性。与对照组相比,研究组患者的血清mi R-103水平明显更高(P<0.05),血清Dicer1水平明显更低(P<0.05);上皮性卵巢癌患者血清中mi R-103高表达41例,低表达17例,Ⅲ、Ⅳ期患者的血清mi R-103水平更高(P<0.05);淋巴结转移阳性患者的血清mi R-103水平更高(P<0.05);上皮性卵巢癌患者血清中Dicer1高表达20例,低表达38例,Ⅰ、Ⅱ期患者的血清Dicer1水平更高(P<0.05);淋巴结转移阴性患者的血清Dicer1水平更高(P<0.05)。上皮性卵巢癌患者血清中mi RNA-103水平显著升高,Dicer1水平均显著下降,且mi R-103、Dicer的高表达均分别与上皮性卵巢癌患者的分期、淋巴结转移密切相关。
This study was to investigate the expression and significance of serum micro RNA-103 and Dicer1 in epithelial ovarian cancer.From April 2013 to December 2015,58 patients with epithelial ovarian cancer were treated in the author’s hospital as the study group,and 36 healthy subjects were collected as the control group.Serum micro RNA-103(mi R-103)and Dicer1 levels were measured by real-time RT-PCR.The expression of two biomarkers in epithelial ovarian cancer and its correlation with clinicopathological features were analyzed.Compared with the control group,the serum mi R-103 level in the study group was significantly higher(P<0.05),and the serum Dicer1 level was significantly lower(P<0.05).In the patients with epithelial ovarian cancer,the expression of mi R-103 was high in 41 cases and low in 17 cases.The serum mi R-103 levels in patients with stage III and IV were higher(P<0.05).Serum mi R-103 levels were higher in patients with positive lymph node metastasis(P<0.05).In patients with epithelial ovarian cancer,Dicer1 was highly expressed in 20 cases and low in 38 cases.Serum Dicer1 levels were higher in patients with stage I and II(P<0.05).Serum Dicer1 levels were higher in patients with negative lymph node metastasis(P<0.05).The serum levels of mi R-103 and Dicer1 in patients with epithelial ovarian cancer were significantly increased and decreased,and the high expression of mi R-103 and Dicer were closely related to the stage and lymph node metastasis of patients with epithelial ovarian cancer.
作者
王熙
周栩茹
WANG Xi;ZHOU Xu-ru(Department of Gynecology,The No.2 People's Hospital of Yichang&The No.2 People's Hospital of China Three Gorges University,Yichang 443000,China)
出处
《药物生物技术》
CAS
2020年第4期329-332,共4页
Pharmaceutical Biotechnology